UBS Group
PCVX icon

UBS Group’s Vaxcyte PCVX Stock Holding History

UBS Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.1M Sell
776,511
-560,879
-42% -$30.5M 0.01% 1852
2026
Q1 		$77.7M Buy
1,337,390
+243,797
+22% +$13.2M 0.01% 1241
2025
Q4 		$50.5M Buy
1,093,593
+246,020
+29% +$11M 0.01% 1623
2025
Q3 		$30.5M Sell
847,573
-533,280
-39% -$17.7M ﹤0.01% 2115
2025
Q2 		$44.9M Buy
1,380,853
+300,457
+28% +$9.85M 0.01% 1621
2025
Q1 		$40.8M Buy
1,080,396
+343,835
+47% +$27.5M 0.01% 1673
2024
Q4 		$60.3M Buy
736,561
+624,988
+560% +$62.1M 0.01% 1299
2024
Q3 		$12.7M Buy
111,573
+15,897
+17% +$1.43M ﹤0.01% 2156
2024
Q2 		$7.22M Sell
95,676
-80,402
-46% -$5.47M ﹤0.01% 2510
2024
Q1 		$12M Buy
176,078
+10,044
+6% +$696K ﹤0.01% 2117
2023
Q4 		$10.4M Buy
166,034
+91,729
+123% +$4.76M ﹤0.01% 2055
2023
Q3 		$3.79M Buy
74,305
+28,483
+62% +$1.41M ﹤0.01% 2848
2023
Q2 		$2.29M Buy
45,822
+45,478
+13,220% +$2.16M ﹤0.01% 3397
2023
Q1 		$12.9K Sell
344
-122,376
-100% -$5.19M ﹤0.01% 7424
2022
Q4 		$5.88M Buy
122,720
+122,645
+163,527% +$4.81M ﹤0.01% 2343
2022
Q3 		$2K Sell
75
-23,498
-100% -$596K ﹤0.01% 9758
2022
Q2 		$513K Sell
23,573
-36,814
-61% -$852K ﹤0.01% 4243
2022
Q1 		$1.46M Buy
60,387
+15,152
+33% +$331K ﹤0.01% 3744
2021
Q4 		$1.08M Sell
45,235
-76,552
-63% -$1.78M ﹤0.01% 4323
2021
Q3 		$3.09M Buy
121,787
+13,884
+13% +$337K ﹤0.01% 3176
2021
Q2 		$2.43M Sell
107,903
-7,547
-7% -$155K ﹤0.01% 3402
2021
Q1 		$2.28M Buy
115,450
+47,284
+69% +$1.19M ﹤0.01% 3428
2020
Q4 		$1.81M Buy
68,166
+67,446
+9,368% +$2.51M ﹤0.01% 3489
2020
Q3 		$36K Buy
+720
New +$28.7K ﹤0.01% 5866

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS Group's PCVX Position: Q2 2026 in Review

UBS Group reduced its Vaxcyte (PCVX) stake by 42% in Q2 2026, selling an estimated $30.5M and leaving 776,511 shares worth $45.1M. The position accounts for 0.01% of the portfolio, ranked #1852.

UBS Group first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $77.7M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • UBS Group held 776,511 shares of Vaxcyte worth $45.1M as of Q2 2026.
  • UBS Group sold 560,879 Vaxcyte shares in Q2 2026, an estimated $30.5M.
  • Vaxcyte made up 0.01% of UBS Group's portfolio in Q2 2026, its #1852 holding.
  • UBS Group first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • UBS Group's Vaxcyte position peaked at $77.7M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.